{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T06:18:03.284693+00:00","company":{"ticker":"QTTB","cik":1661998,"company_name":"Q32 Bio Inc."},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"cb541179af3d4151c0532f6aa5ef7e966fbf056c","cik":1661998,"ticker":"QTTB","company_name":"Q32 Bio Inc.","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":"$0.54 basic and diluted net loss per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $7.6 million, or $0.54 basic and diluted net loss per share","period_text":"the quarter ended March 31, 2026","report_date":"2026-05-05","result_type":"reported_results","revenue_text":null},"claim":"Q32 Bio Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $7.6 million, or $0.54 basic and diluted net loss per share, EPS $0.54 basic and diluted net loss per share.","evidence_excerpt":"Net loss was $7.6 million, or $0.54 basic and diluted net loss per share, for the three months ended March 31, 2026, compared to net loss of $11.0 million, or $0.90 basic and diluted net loss per share, for the three months ended March 31, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-205006","anchor_url":"https://secwatch.observer/filing/0001193125-26-205006#claim-cb541179af3d4151c0532f6aa5ef7e966fbf056c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526205006/0001193125-26-205006-index.htm"},{"fact_type":"material_agreement","fact_key":"3ab6ecd1b7f45cedf425ca28083963f6c461c268","cik":1661998,"ticker":"QTTB","company_name":"Q32 Bio Inc.","filed_at":"2026-03-27T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Controlled Equity Offering SM Sales Agreement","agreement_type":"atm_program","counterparty":"Cantor Fitzgerald & Co.","effective_date":"2026-03-27","item_codes_triggered":["1.01"],"value_text":"up to $14,200,000"},"claim":"Q32 Bio Inc. entered into Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. valued at up to $14,200,000 (effective 2026-03-27).","evidence_excerpt":"On March 27, 2026, Q32 Bio Inc. (the “Company”) entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Sales Agent”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-129431","anchor_url":"https://secwatch.observer/filing/0001193125-26-129431#claim-3ab6ecd1b7f45cedf425ca28083963f6c461c268","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526129431/0001193125-26-129431-index.htm"},{"fact_type":"material_agreement","fact_key":"93b3a6557b78e4479deef0bc03609e5da85ae02a","cik":1661998,"ticker":"QTTB","company_name":"Q32 Bio Inc.","filed_at":"2026-02-17T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain institutional investors","effective_date":"2026-02-17","item_codes_triggered":["1.01"],"value_text":"approximately $10.5 million"},"claim":"Q32 Bio Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $10.5 million (effective 2026-02-17).","evidence_excerpt":"On February 17, 2026, Q32 Bio Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors relating to the issuance and sale of (i) 1,666,679 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $3.90 per share, and (ii) pre-funded warrants to purchase 1,025,654 shares of Common Stock (the “Pre-Funded Warrants”), to such investors in a registered direct offering (the “Offering”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-054711","anchor_url":"https://secwatch.observer/filing/0001193125-26-054711#claim-93b3a6557b78e4479deef0bc03609e5da85ae02a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526054711/0001193125-26-054711-index.htm"},{"fact_type":"ma_transaction","fact_key":"96d4d89f439239fec2454586078f69dc21df07f6","cik":1661998,"ticker":"QTTB","company_name":"Q32 Bio Inc.","filed_at":"2025-12-01T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2025-11-28","consideration_text":"$7.0 million upfront","counterparty":"Akebia Therapeutics, Inc.","effective_date":"2025-11-28","item_codes_triggered":["2.01"]},"claim":"Q32 Bio Inc. completed a disposition involving Akebia Therapeutics, Inc. for $7.0 million upfront (closed 2025-11-28).","evidence_excerpt":"will be responsible for any future development and commercialization of ADX-097. As consideration for the ADX-097 Asset Sale, the Company (i) received an upfront payment of $7.0 million on the Closing Date, and (ii) will receive a payment of $3.0 million on the six-month anniversary of the Closing Date. The Company will also receive a near-term milestone payment","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-303115","anchor_url":"https://secwatch.observer/filing/0001193125-25-303115#claim-96d4d89f439239fec2454586078f69dc21df07f6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312525303115/0001193125-25-303115-index.htm"},{"fact_type":"governance_change","fact_key":"8bc9cc59e82d2874f8601fa61d4f6ba38d19e887","cik":1661998,"ticker":"QTTB","company_name":"Q32 Bio Inc.","filed_at":"2025-06-17T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-06-16","item_codes_triggered":["5.03"],"summary_text":"Approved amendment to Restated Certificate of Incorporation to limit liability of certain officers as permitted by Delaware law."},"claim":"Q32 Bio Inc.: Approved amendment to Restated Certificate of Incorporation to limit liability of certain officers as permitted by Delaware law (effective 2025-06-16).","evidence_excerpt":"on June 13, 2025 at the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Q32 Bio Inc. (the “Company”), and upon the recommendation of the Board of Directors (the “Board”) of the Company, the Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”) to limit the liability of certain officers of the Company as permitted by Delaware law (the “Charter Amendment”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-142039","anchor_url":"https://secwatch.observer/filing/0001193125-25-142039#claim-8bc9cc59e82d2874f8601fa61d4f6ba38d19e887","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312525142039/0001193125-25-142039-index.htm"},{"fact_type":"executive_change","fact_key":"740b5c74b7","cik":1661998,"ticker":"QTTB","company_name":"Q32 Bio Inc.","filed_at":"2025-04-25T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-12-31","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Mark Iwicki resigned as Director at Q32 Bio Inc..","evidence_excerpt":"On April 25, 2025, Mark Iwicki provided notice of his resignation from the board of directors (the “Board”) of Q32 Bio Inc. (the “Company”), effective as of December 31, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-096703","anchor_url":"https://secwatch.observer/filing/0001193125-25-096703#claim-740b5c74b7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312525096703/0001193125-25-096703-index.htm"},{"fact_type":"earnings_release","fact_key":"de638b8f5b128432425b5892258111cb54c389f8","cik":1661998,"ticker":"QTTB","company_name":"Q32 Bio Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":"$1.03 basic net income per share and ($6.33) diluted net loss per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$1.0 million","period_text":"the quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":null},"claim":"Q32 Bio Inc. reported the quarter ended March 31, 2024 results: net income $1.0 million, EPS $1.03 basic net income per share and ($6.33) diluted net loss per share.","evidence_excerpt":"Q32 Bio Inc. announced its financial results for the quarter ended March 31, 2024","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-056256","anchor_url":"https://secwatch.observer/filing/0000950170-24-056256#claim-de638b8f5b128432425b5892258111cb54c389f8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1661998/000095017024056256/0000950170-24-056256-index.htm"}]}